Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.
about
Nanotechnology-based drug delivery systems for the treatment of Alzheimer's diseaseNanotechnologies for noninvasive measurement of drug releaseBiodistribution and Toxicity Studies of PRINT Hydrogel Nanoparticles in Mosquito Larvae and CellsPolymeric Nanostructures for Imaging and TherapyExtracellularly activatable nanocarriers for drug delivery to tumors.Development of nanoscale approaches for ovarian cancer therapeutics and diagnosticsNanoparticle clearance is governed by Th1/Th2 immunity and strain background.Subtumoral analysis of PRINT nanoparticle distribution reveals targeting variation based on cellular and particle propertiesDocetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancerStrategies for advancing cancer nanomedicine.EFFECTS OF POLYMERIC NANOPARTICLE SURFACE PROPERTIES ON INTERACTION WITH BRAIN TUMOR ENVIRONMENT.Future of the particle replication in nonwetting templates (PRINT) technologyAnalysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles.Preparation and biological evaluation of synthetic and polymer-encapsulated congeners of the antitumor agent pactamycin: insight into functional group effects and biological activity.Shape Control in Engineering of Polymeric Nanoparticles for Therapeutic Delivery.Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Shaping the future of nanomedicine: anisotropy in polymeric nanoparticle designTranslocation of LRP1 targeted carbon nanotubes of different diameters across the blood-brain barrier in vitro and in vivoBiomaterials and emerging anticancer therapeutics: engineering the microenvironment.Reductively Responsive Hydrogel Nanoparticles with Uniform Size, Shape, and Tunable Composition for Systemic siRNA Delivery in Vivo.Emergence and Utility of Nonspherical Particles in BiomedicineFormulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity.Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium.Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles.Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacyDocetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.Guiding principles in the design of ligand-targeted nanomedicines.Differences in physicochemical properties to consider in the design, evaluation and choice between microparticles and nanoparticles for drug delivery.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Biomimetic particles as therapeutics.Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation.Nanocarriers for spleen targeting: anatomo-physiological considerations, formulation strategies and therapeutic potential.Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.Nanoparticulate fingolimod delivery system based on biodegradable poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV): design, optimization, characterization and in-vitro evaluation.Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.An automated multidimensional thin film stretching device for the generation of anisotropic polymeric micro- and nanoparticles.Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.Engineered PRINT(®) nanoparticles for controlled delivery of antigens and immunostimulants.
P2860
Q26783306-A611AD56-E9BD-4C94-8D9C-275F2BE0F4ECQ28387499-C1884141-1469-41E5-B2A2-4BBF75DF2493Q28547397-D945B1E1-B6F5-4B1A-8848-8FD50DC8C8ECQ30372383-C3EC8587-EAD1-46E9-9C31-F94DCA006DCDQ30401826-AB6962AE-0542-453C-AC58-6D1AB8EC47AAQ30421664-8729007B-4C77-48B9-BF38-CE32D8A7347EQ30541000-1E192095-8CEB-45BD-B292-E4A7DD6EAF07Q30744724-11B0B5FA-48F9-41ED-8D8F-E2CB44074B5CQ33601365-14C808BD-2A3B-4E51-9049-D5912764B62FQ33875597-D7AE1978-D635-4E84-84AD-407D81C4DC44Q33995719-7BE2656D-970F-4C20-BE33-1C747AF5411AQ34019320-1A4A3B2F-40E3-4645-BCC4-487E9B0C65C0Q34149094-3151C050-2BF1-4CD9-B78C-C37A51A0BAB7Q34675068-EA367283-546C-4100-95F7-FC7FBF7F300AQ35234404-FCC8E719-ED0B-4002-8321-30D65C6ADD83Q35801327-E292A4EF-783C-4A09-8CB2-381537417595Q36071814-01301197-151C-4254-9FC3-527B1D8329B0Q36126057-ACC2E7CF-9501-4E58-B79C-AFD711F9735AQ36279715-68E57759-0D2F-45F1-B688-6B793D839D6FQ36652635-9E660772-65D8-4EF6-B5DD-28D75B6CB2AEQ36684345-28E8907D-A9BD-46F7-9412-4871D106545DQ36821612-46A13FB8-40D0-4D62-A10B-9F35EA37C4F7Q36892538-F3FF7F8F-34EE-423F-BD65-EF456D5C0EDDQ36949647-785D8147-E407-4E56-AC18-79E027376C18Q36967705-7CF9D3F3-A990-43FC-9A8F-C8D56A7646D0Q37188521-76C2C3DB-CABD-4912-96CC-51B4412E446EQ37253857-D76AC99B-C2B0-483C-9AFE-C7DB10F945B2Q37623841-70ED1A02-C7A1-4C98-818A-4C9E24D9517FQ38189490-88D03350-D47C-4A17-9B1D-B6A39579A92EQ38291341-B4757FCF-FC5B-4633-B407-3D365B44ADE0Q38546964-72D9CF1A-6C8A-44F2-9BFC-A53537A45762Q38567436-1C535790-6692-4E32-9F1A-CF3A55573992Q38691793-15B4FFB6-A08E-4567-8731-B250E3AA8499Q38873739-EB6E78FB-46B4-481D-A39F-2E351D2003D4Q39458957-B9006988-6F12-4635-BBB6-57CCFBD9C1B1Q40336488-86928DC3-7F7A-4D47-A207-51FE00302FF7Q41280444-078DDC42-46DF-449B-A934-D2697DEF0F1DQ41495734-2A9AA0BF-276C-42EB-91D9-4BCD4778EC51Q42109453-AAFCBD13-C63E-4181-A934-AE65864E460AQ42206456-C260E9F7-820B-46FD-82C3-9BC9B647FC10
P2860
Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@ast
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@en
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@nl
type
label
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@ast
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@en
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@nl
prefLabel
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@ast
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@en
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@nl
P2093
P2860
P1476
Plasma, tumor and tissue pharm ...... n ovarian carcinoma xenograft.
@en
P2093
Arlene S Bridges
Elizabeth M Enlow
J Christopher Luft
Jennifer L Kuijer
Joseph M DeSimone
Kevin S Chu
Mark D Walsh
Mary E Napier
Sumit Rawal
Warefta Hasan
P2860
P304
P356
10.1016/J.NANO.2012.11.008
P577
2012-12-06T00:00:00Z